<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00425334</url>
  </required_header>
  <id_info>
    <org_study_id>6012</org_study_id>
    <nct_id>NCT00425334</nct_id>
  </id_info>
  <brief_title>Safety Study of Hemospan® in Prostatectomy Patients</brief_title>
  <official_title>A Clinical Safety (Phase II) Increasing Dose Study of MP4 (Hemospan®) in Total Prostatectomy Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sangart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sangart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a progressive dose escalation study designed to evaluate the safety of Hemospan&#xD;
      compared to a standard crystalloid solution (Ringer's lactate) in elective surgery patients&#xD;
      undergoing total prostatectomy procedures with anticipated blood loss of more than 500 mL.&#xD;
      Secondary objectives of this study are to observe possible activity of Hemospan for tissue&#xD;
      oxygenation, perfusion and cardiovascular support.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Donor (allogeneic) blood transfusions are often required during and/or after elective surgery&#xD;
      to maintain adequate hemoglobin concentration, prevent tissue ischemia (inadequate&#xD;
      perfusion), treat hypotension (low blood pressure), and compensate for fluid shifts. Hemospan&#xD;
      is a novel hemoglobin-based oxygen carrier and plasma expander specifically developed to&#xD;
      perfuse and oxygenate tissue at risk for ischemia and hypoxia (insufficient oxygenation). As&#xD;
      a result of the molecular size and oxygen dissociation characteristics, Hemospan selectively&#xD;
      off-loads oxygen in tissues predisposed to low oxygen tension.&#xD;
&#xD;
      In preclinical studies Hemospan has been found to be free of significant toxicity in a&#xD;
      variety of animal species. These studies have also demonstrated that Hemospan may be ideally&#xD;
      suited for this application, and may even perform better than blood in certain situations.&#xD;
      Hemospan has been evaluated in three clinical studies, including a 90-patient multi-center&#xD;
      Phase II orthopedic surgery trial completed in Sweden in 2005. No serious adverse events&#xD;
      attributable to Hemospan have been noted in any of these trials.&#xD;
&#xD;
      Sangart is developing Hemospan as an oxygen-carrying plasma expander and hemodiluent for&#xD;
      patients undergoing elective surgical procedures. In the current Phase II study in&#xD;
      prostatectomy patients, the administration of Hemospan (Treatment) or Ringer's lactate&#xD;
      (Controls) occurs after approximately 250 mL of surgical blood loss has occurred. Study&#xD;
      evaluations include clinical observations, subjective symptoms, vital signs, ECG, pulmonary&#xD;
      hemodynamics (by TEE), serum chemistry, hematology, urinalysis, renal function, and&#xD;
      oxygenation measurements, as well as a safety follow-up assessment at 4-6 weeks after&#xD;
      surgery. An independent Data Safety Monitoring Board (DSMB) will review the safety data&#xD;
      following completion of each dosing cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in oxygenation, perfusion and cardiovascular status</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and type of cardiac rhythm disturbances</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and duration of intraoperative hypotensive episodes</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pharmacologic interventions for cardiovascular support</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of supplemental oxygen use</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of intravenous fluid administered</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood products administered</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Blood Loss, Surgical</condition>
  <condition>Prostate Cancer</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Hemospan (MP4OX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4.3 g/dL MalPEG-Hb solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ringer's lactate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hemospan (MP4OX)</intervention_name>
    <description>250 mL or 500 mL Hemospan (MP4OX)</description>
    <arm_group_label>Hemospan (MP4OX)</arm_group_label>
    <other_name>MP4OX solution</other_name>
    <other_name>4.3 g/dL MalPEG Hb</other_name>
    <other_name>PEGylated Hb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ringer's lactate</intervention_name>
    <description>250 mL or 500 mL Ringer's lactate USP</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Lactated Ringers</other_name>
    <other_name>Ringers solution</other_name>
    <other_name>Hartmann's solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male ASA class I or II patients over the age of 18 scheduled for elective total&#xD;
             prostatectomy surgery with anticipated blood loss greater than 500 mL&#xD;
&#xD;
          -  Patients must be in good health (other than the indication for prostatectomy surgery)&#xD;
             as determined by medical history, physical examination, clinical laboratory studies&#xD;
             and electrocardiogram (ECG)&#xD;
&#xD;
          -  At screening (within 2 weeks of the scheduled surgery) the blood chemistry and&#xD;
             hematology (Hb, Hct, RBC, WBC, platelets, PT, PTT, plasma fibrinogen, fibrin split&#xD;
             products and haptoglobin) must be within the laboratory normal limits&#xD;
&#xD;
          -  Patients must test negative for HIV and hepatitis screens&#xD;
&#xD;
          -  Patients must sign an Informed Consent Form (see Appendix II) for the study, which has&#xD;
             been reviewed and approved by the Institutional Review Board, prior to screening and&#xD;
             entry into the study&#xD;
&#xD;
          -  Patients must be available within the continental United States for the period of this&#xD;
             study, and willing to complete the follow-up at 4-6 weeks&#xD;
&#xD;
          -  Patients must be able to understand and read English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any acute or chronic condition which would limit the patient's ability to complete the&#xD;
             study or jeopardize the safety of the patient&#xD;
&#xD;
          -  History or clinical manifestations of a significant cardiovascular or pulmonary&#xD;
             disorder&#xD;
&#xD;
          -  Clinically significant psychiatric disorder requiring active treatment&#xD;
&#xD;
          -  History of diabetes requiring active treatment&#xD;
&#xD;
          -  History or clinical manifestation of significant renal or hepatic disorder&#xD;
&#xD;
          -  History of thyroid disease or clinical symptoms consistent with thyroid disease&#xD;
&#xD;
          -  History of bleeding disorder&#xD;
&#xD;
          -  History or family history of a hemoglobinopathy&#xD;
&#xD;
          -  Patients with contraindications to TEE probe insertion&#xD;
&#xD;
          -  Patients who have received any other investigational drugs within 30 days prior to&#xD;
             administration of the study drug&#xD;
&#xD;
          -  Professional or ancillary personnel involved with this study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Ulatowski, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter E. Keipert, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Sangart, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institutions</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sangart.com</url>
    <description>Click here for more information about Sangart, Inc.</description>
  </link>
  <reference>
    <citation>Björkholm M, Fagrell B, Przybelski R, Winslow N, Young M, Winslow RM. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol. Haematologica. 2005 Apr;90(4):505-15.</citation>
    <PMID>15820947</PMID>
  </reference>
  <reference>
    <citation>Young MA, Riddez L, Kjellström BT, Bursell J, Winslow F, Lohman J, Winslow RM. MalPEG-hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine. Crit Care Med. 2005 Aug;33(8):1794-804.</citation>
    <PMID>16096458</PMID>
  </reference>
  <reference>
    <citation>Tsai AG, Cabrales P, Manjula BN, Acharya SA, Winslow RM, Intaglietta M. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood. 2006 Nov 15;108(10):3603-10. Epub 2006 Jul 20.</citation>
    <PMID>16857991</PMID>
  </reference>
  <reference>
    <citation>Winslow RM. Current status of oxygen carriers ('blood substitutes'): 2006. Vox Sang. 2006 Aug;91(2):102-10. Review.</citation>
    <PMID>16907870</PMID>
  </reference>
  <reference>
    <citation>Olofsson C, Ahl T, Johansson T, Larsson S, Nellgård P, Ponzer S, Fagrell B, Przybelski R, Keipert P, Winslow N, Winslow RM. A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery. Anesthesiology. 2006 Dec;105(6):1153-63.</citation>
    <PMID>17122578</PMID>
  </reference>
  <reference>
    <citation>Winslow RM. Red cell substitutes. Semin Hematol. 2007 Jan;44(1):51-9. Review.</citation>
    <PMID>17198847</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>January 18, 2007</study_first_submitted>
  <study_first_submitted_qc>January 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2007</study_first_posted>
  <last_update_submitted>August 15, 2013</last_update_submitted>
  <last_update_submitted_qc>August 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood loss</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Blood Substitutes</keyword>
  <keyword>Plasma Expanders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

